Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin’s lymphoma

This phase II clinical trial evaluated the efficacy, safety and pharmacokinetics of plitidepsin 3.2 mg/m(2) administered as a 1-hour intravenous infusion weekly on days 1, 8 and 15 every 4 weeks in 67 adult patients with relapsed/refractory aggressive non-Hodgkin’s lymphoma. Patients were divided in...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Ribrag, Vincent, Caballero, Dolores, Fermé, Christophe, Zucca, Emanuele, Arranz, Reyes, Briones, Javier, Gisselbrecht, Christian, Salles, Gilles, Gianni, Alessandro M., Gomez, Henry, Kahatt, Carmen, Corrado, Claudia, Szyldergemajn, Sergio, Extremera, Sonia, de Miguel, Bernardo, Cullell-Young, Martin, Cavalli, Franco
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Ferrata Storti Foundation 2013
विषय:
Articles
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC3659946/
https://ncbi.nlm.nih.gov/pubmed/23065525
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2012.069757
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन